choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Rebif

Rebif Newsletter
  • Full list of drugs that could be slashed under Trump's new executive order 13 May 2025 09:11 GMT

    … narrowly covered Medicare Part B drugs, including immunosuppressants … (far right) Cancer Treatments (Chemotherapy & Immunotherapy … Cost Therapies 1. Rebif (interferon beta-1a … systems negotiate drug prices directly with pharmaceutical companies, bypassing …

  • FDA approves first drug to treat multiple sclerosis — Ocrevus for primary progressive MS 05 May 2025 21:57 GMT

    … in the FDA’s Center for Drug Evaluation and … treatment of relapsing forms of MS was shown in two clinical trials … compared Ocrevus to another MS drug, Rebif (interferon beta-1a). … patient Medication Guide that describes important information about the drug’ …

  • MS Drug — Ampyra: A New Gait For Independence 24 Apr 2025 09:03 GMT

    … 2010, the US Federal Drug Administration (FDA) approved AMPRYA (dalfampridine) … of Acorda Therapeutics, a biotechnology company based in Hawthorne, … the formulation from Elan Pharmaceuticals, which continues to manufacture … access to the treatment. ampyra.com

  • Optum Rx Ends Reauthorization for Many Chronic Disease Drugs 19 Mar 2025 18:04 GMT

    … condition Requires chronic treatment Long-term drug effectiveness is established … , Alyftrek Multiple sclerosis drugs: Mavenclad, Plegridy, Lemtrada, Rebif, Ponvory, Extavia, Kesimpta … for procedures and services in Medicare Advantage plans. The healthcare …

  • Rebif Market Forecast 2025-2034: Comprehensive Insights On Market Size, Growth Factors, Trends, Competitive Landscape 12 Mar 2025 03:43 GMT

    … Shift toward combination treatments. o Higher adoption of personalized medicine. o Rising … market include: o Advancements in drug delivery systems. o Regulatory reforms … thebusinessresearchcompany.com/report/rebif-global-market-report Who are …

  • Briumvi interactions: Alcohol, medications, and other factors 13 Feb 2025 14:54 GMT

    … 1a (Avonex, Rebif) natalizumab (Tysabri) Steps you or your doctor may take … or symptoms of infection during treatment. Briumvi may have other interactions … your doctor or another healthcare professional before taking any medication. The drug information …

  • Global Rebif Market Growth: Projected to Reach XX Billion by 2029 with an Impressive XX% CAGR 06 Feb 2025 17:24 GMT

    … therapies, widespread adoption of personalized medicine, and increasing diagnosis of … in drug delivery systems, regulatory reformations, integration of artificial intelligence in treatmentmedicine are amongst the major trends shaping the future of the rebif

  • Understanding Multiple Sclerosis: Types, symptoms, and treatment options 31 Jan 2025 04:17 GMT

    … ) Visual evoked potentials (VEP) Treatment Medication and therapies can help manage … such as: Rebif Plegridy Extravia Betaseron Avonex Oral medication for RRMS include … (Gilenya) Intravenous (IV) infusion treatment for RRMS include: Ocrelizumab (Ocrevus …

  • Rebif side effects: What you should know 29 Jan 2025 15:09 GMT

    … who used Rebif in clinical trials: Mild … doctor or pharmacist. Note: After the Food and Drug Administration (FDA) approves a drugRebif, your doctor may recommend taking a different medication instead. Rebif … you should continue Rebif treatment. If you have …

  • Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics 31 Jan 2025 13:11 GMT

    … products for the treatment of neurodegenerative diseases and … combined Nasdaq-traded biotechnology company with a … of Rebif®, a multiple sclerosis blockbuster drug sold worldwide … with-nls-pharmaceutics-302365225.html SOURCE NLS Pharmaceutics Ltd.; …

Satisfied with the content?

Continue to create your account.